Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Jop Mostert et al.|JAMA Neurology|2024Cited by 29
Scanner-specific optimisation of automated lesion segmentation in MSDavid R. van Nederpelt, Hugo Vrenken, Menno M. Schoonheim et al.|NeuroImage Clinical|2024Cited by 6
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Jop Mostert et al.|Journal of Neurology|2025Cited by 4
Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosisMar Barrantes-Cepas, Menno M. Schoonheim, Nicola De Stefano et al.|Multiple Sclerosis Journal|2025Cited by 2